Publication | Open Access

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

Geriatric NeurologyAlzheimer's DiseaseMedicineDementiaIntravenous ImmunoglobulinImmunologyClinical TrialsVascular DementiaNeurologyAging-associated DiseasePhase 2NeuroimmunologyTreatmentDose-finding TrialHealth Sciences